Índice
Literatura académica sobre el tema "Lipid nanovectors"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Lipid nanovectors".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Lipid nanovectors"
Sánchez-Arribas, Natalia, María Martínez-Negro, Clara Aicart-Ramos, Conchita Tros de Ilarduya, Emilio Aicart, Andrés Guerrero-Martínez y Elena Junquera. "Gemini Cationic Lipid-Type Nanovectors Suitable for the Transfection of Therapeutic Plasmid DNA Encoding for Pro-Inflammatory Cytokine Interleukin-12". Pharmaceutics 13, n.º 5 (15 de mayo de 2021): 729. http://dx.doi.org/10.3390/pharmaceutics13050729.
Texto completoBéduneau, Arnaud, François Hindré, Anne Clavreul, Jean-Christophe Leroux, Patrick Saulnier y Jean-Pierre Benoit. "Brain targeting using novel lipid nanovectors". Journal of Controlled Release 126, n.º 1 (febrero de 2008): 44–49. http://dx.doi.org/10.1016/j.jconrel.2007.11.001.
Texto completoTapeinos, Christos, Attilio Marino, Matteo Battaglini, Simone Migliorin, Rosaria Brescia, Alice Scarpellini, César De Julián Fernández, Mirko Prato, Filippo Drago y Gianni Ciofani. "Stimuli-responsive lipid-based magnetic nanovectors increase apoptosis in glioblastoma cells through synergic intracellular hyperthermia and chemotherapy". Nanoscale 11, n.º 1 (2019): 72–88. http://dx.doi.org/10.1039/c8nr05520c.
Texto completoCampani, Virginia, Giuseppina Salzano, Sara Lusa y Giuseppe De Rosa. "Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer". Nanomaterials 6, n.º 7 (9 de julio de 2016): 131. http://dx.doi.org/10.3390/nano6070131.
Texto completoClemente, Ilaria, Stefania Lamponi, Gabriella Tamasi, Liliana Rodolfi, Claudio Rossi y Sandra Ristori. "Structuring and De-Structuring of Nanovectors from Algal Lipids: Simulated Digestion, Preliminary Antioxidant Capacity and In Vitro Tests". Pharmaceutics 14, n.º 9 (1 de septiembre de 2022): 1847. http://dx.doi.org/10.3390/pharmaceutics14091847.
Texto completoArpicco, Silvia, Giuseppe De Rosa y Elias Fattal. "Lipid-Based Nanovectors for Targeting of CD44-Overexpressing Tumor Cells". Journal of Drug Delivery 2013 (7 de marzo de 2013): 1–8. http://dx.doi.org/10.1155/2013/860780.
Texto completoGangupomu, Vamshi K. y Franco M. Capaldi. "Interactions of Carbon Nanotube with Lipid Bilayer Membranes". Journal of Nanomaterials 2011 (2011): 1–6. http://dx.doi.org/10.1155/2011/830436.
Texto completoPardeshi, Chandrakantsing, Pravin Rajput, Veena Belgamwar, Avinash Tekade, Ganesh Patil, Kapil Chaudhary y Abhijeet Sonje. "Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled". Acta Pharmaceutica 62, n.º 4 (1 de diciembre de 2012): 433–72. http://dx.doi.org/10.2478/v10007-012-0040-z.
Texto completoVaccaro, Mauro, Raffaella Del Litto, Gaetano Mangiapia, Anna M. Carnerup, Gerardino D’Errico, Francesco Ruffo y Luigi Paduano. "Lipid based nanovectors containing ruthenium complexes: a potential route in cancer therapy". Chemical Communications, n.º 11 (2009): 1404. http://dx.doi.org/10.1039/b820368g.
Texto completoDepalo, N., V. De Leo, M. Corricelli, R. Gristina, G. Valente, E. Casamassima, R. Comparelli et al. "Lipid-based systems loaded with PbS nanocrystals: near infrared emitting trackable nanovectors". Journal of Materials Chemistry B 5, n.º 7 (2017): 1471–81. http://dx.doi.org/10.1039/c6tb02590k.
Texto completoTesis sobre el tema "Lipid nanovectors"
Dumont, Camille. "Nanovecteurs lipidiques pour la délivrance orale de peptides". Thesis, Lyon, 2020. http://www.theses.fr/2020LYSE1022.
Texto completoTherapeutic peptides are able to treat a wide variety of diseases with selective and potent action. Their oral bioavailability is strongly limited by an important proteolytic activity in the intestinal lumen and poor permeation across the intestinal border. We have evaluated the capacity of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid carriers (NLC) to overcome both oral bioavailability limiting aspects, using Leuprolide (LEU) as model peptide. Lipidization of LEU by formation of a Hydrophobic Ion Pair (HIP) with docusate enables a significant increase of peptide encapsulation efficiency in both SLN and NLC. The nanocarriers, obtained by high pressure homogenization, measured 120 nm and were stable in simulated gastro-intestinal fluids. However, due to particles platelet-shape, an important quantity of LEU is released in simulated fasted state intestinal fluid. Regarding the protective effect towards proteolytic degradation, only NLC maintain LEU integrity in presence of trypsin. Intestinal transport, evaluated on Caco-2 (enterocyte-like model) and Caco-2/HT29-MTX (mucin-secreting model) monolayers, show nanocarriers internalization by enterocytes but no improvement of LEU permeability. Indeed, the combination of nanoparticles platelet-shape with the poor stability of the HIP in the transport medium induces a high burst release of the peptide, limiting nanoparticles capacity to transport LEU across the intestinal border. Stability of peptide lipidization needs to be improved to withstand biorelevant medium to benefit from the advantages of encapsulation in solid lipid nanocarriers and consequently improve their oral bioavailability
Zerkoune, Leïla. "Développement de nanovecteurs multicompartimentaux à base de cyclodextrines amphiphiles et de lipides pour des applications en nanomédecine". Thesis, Paris 11, 2015. http://www.theses.fr/2015PA114837.
Texto completoThe key idea of this Ph.D. thesis is to introduce amphiphilic β-cyclodextrin molecules (βCD), obtained by bio-transesterification, within lipid mesophases in order to obtain multi-compartment plurimolecular nano-assemblies, which combine three essential functions for transport or delivery of therapeutic molecules: (i) capacity to incorporate a substance of interest through formation of inclusion complexes with the modified cyclodextrin; (i) biocompatibility and ability to easily pass the biological barriers; and (iii) possibility for co-encapsulation of a second substance of interest, a hydrophilic or a hydrophobic one, whose biological action is different from that provided by the first substance. The performed Ph. D. work focused on the β-cyclodextrin derivative βCD-C10 with an average degree of substitution of 7.5 of the secondary face of the macrocycle by hydrocarbon chains C10. The association of this derivative with three classes of amphiphiles was studied: (i) nonionic micellar surfactants (Brij 98, Polysorbate 80, n-dodecyl β-D-maltoside), (ii) a lyotropic nonlamellar lipid forming bicontinuous cubic mesophases (monoolein), and (iii) a phospholipid (dimyristoyl phosphatidylcholine), which self-ssembles into bilayer membranes permitting the production of vesicles.The employed physical-chemical approach involved different techniques for characterization of the mixed βCD-C10/lipid systems at molecular and supramolecular levels: cryo-transmission electron microscopy, X-ray diffraction, differential scanning calorimetry, UV-visible absorption spectroscopy, fluorescence spectroscopy, turbidimetry, and quasi-elastic light scattering.The obtained results indicated that the βCD-C10 derivative forms spontaneously (or via a very simple preparation protocol) plurimolecular mixed nano-assemblies with the three types of lipids. The topologies of the resulting nano-assemblies essentially depend on the chemical structures of the lipids and the degree of incorporation of the amphiphilic cyclodextrin (tubules, unilamellar or oligolamellar vesicles, and cubosomes). These assemblies, namely the mixed vesicles of nonionic surfactant/βCD-C10 and the cubosomes of mixed monoolein/P80/βCD-C10 compositions, are stable and capable of incorporation of hydrophobic guest substances
Sala, Mourad. "Nanovecteurs lipidiques pour une application topique dans le psoriasis et sa complication arthritique". Thesis, Lyon, 2017. http://www.theses.fr/2017LYSE1193/document.
Texto completoPsoriasis is an auto-immune and chronic skin disease. Psoriatic arthritis is the main complication which is very disabling for patients. This pathology still remains incurable to date. The currently psoriasis indicated medicines use is limited by their side effects which are dose and use duration dependent. The aim of this work was to develop lipid based nanocarriers for skin targeting, especially the viable epidermis which is the main site of psoriasis physiopathology but also the dermis and beyond in order to reach the damaged articulations. Thanks to a new technique we developed and optimized called the double solvent displacement, based on a two-step phospholipid organization, we prepared diclofenac and cyclosporine A loaded lipid vesicles. Then, we evaluated their potential to cross the skin and target the skin layers of interest. After a systematic study to optimize preparation parameters, diclofenac and cyclosporine A loaded lipid vesicles displayed an encapsulation efficiency (EE %) between 50% and 90% respectively, according to the phospholipid concentration. After in vitro skin studies, we observed that the formulation containing the lower phospholipid concentration (8.5 mg/mL) allowed to encapsulate more than 80% of diclofenac and also to target the dermis and beyond. The formulation of cyclosporine A loaded lipid vesicles which encapsulates the higher amount (around 80%) is also the one containing the lower phospholipid concentration. Unlike to diclofenac, this formulation was not the better to target the viable epidermis whereas the formulation with the higher phospholipid concentration (15 mg/mL) was even though the EE% was of around 55%. The double solvent displacement is a very promising technique of lipid vesicle preparation, capable to produce monodisperse population of nanoscale carriers. This method is hardly impacted during scale-up and would be easy to implement at an industrial scale. This method was designed from the beginning to use skin penetration enhancer solvents but the scope of its applications still remains to be explored
Matha, Kévin. "Développement de nanovecteurs innovants destinés au traitement de la leishmaniose viscérale. Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules The advantages of nanomedicine in the treatment of visceral leishmaniasis: between sound arguments and wishful thinking". Thesis, Angers, 2020. http://www.theses.fr/2020ANGE0027.
Texto completoVisceral Leishmaniasis (VL) is a vector-borne anthropozoonosis caused by aunicellular parasitic protozoan of the Leishmania genus. Among the 20 Leishmania species responsible for human diseases, Leishmania donovani and Leishmania infantum are the two most important agents causing VL and are responsible for substantial health problems affecting 400,000 people per year. The disease is lethal if untreated, leading to the death of 30- 40,000 people yearly and yet the world health organization classified this disease as neglected. In the present work, we proposed the formulation and evaluation of two new types of nanocarriers : the hyaluronic acid/poly-L-arginine nanocomplexes (NCs) associating pentamidine and the lipid nanocapsules loaded with miltefosine (LNCs). Both systems were formulated with a microfluidic device in a continuous process, and both systems were characterized in physicochemical terms. The evaluation of the NCs was pushed further with a freeze-drying and a thorough characterization using several techniques (dynamic lights cattering, static light scattering, multi-angle light scattering, nanotracking analysis). Both systems were hemocompatible as they induced no hemolysis, a moderate to weak complement activation and an extremely low toxicity on macrophages. When assessed on a macrophage/leishmania co-culture model, both systems showed a good efficacy. NCs and LNCs are promising nanomedicines to treat leishmaniasis as they show good signs of potential efficacy, safety, and scale-up possibilities
Menicucci, Felicia. "DEVELOPMENT AND CHARACTERIZATION OF GREEN LIPID-BASED NANOVECTORS FOR AGRICULTURAL APPLICATIONS SVILUPPO E CARATTERIZZAZIONE DI NANOVETTORI LIPIDICI “VERDI” PER APPLICAZIONI AGRONOMICHE". Doctoral thesis, 2020. http://hdl.handle.net/2158/1218504.
Texto completo